 Provider News CaliforniaJuly 2024 Provider NewsletterBeginning with claims processing on or after August 1, 2024, Anthem will use coding policies to support the use of anatomical modifiers. These policies were developed to promote national correct coding methods and to control improper coding that leads to incorrect payment. This update is part of continuing efforts to process claims accurately without having to request additional documentation from care providers. What are the policies for using anatomical modifiers in procedure coding?CPT® and HCPCS Level II guidelines supporting the use of anatomic-specific modifiers were used to develop these policies, which validate the area or part of the body on which a procedure is performed. Procedure codes that do not specify right or left require the appropriate anatomical modifier. If an anatomical modifier is necessary to differentiate right or left and is not appended, the claim will be denied. Likewise, if a modifier is appended to a procedure code that does not match the appropriate anatomical site, the claim will be denied. Action neededCPT and HCPCS Level II guidelines support the following set of anatomical modifiers to facilitate correct coding for claims processing. Care providers are encouraged to follow these guidelines and append the modifiers relevant to the procedure code on the service line. The anatomical modifiers, which must be reported, are: Modifier | Description | E1–E4 | Eyelids | FA, F1–F9 | Fingers | TA, T1–T9 | Toes | LC | Left circumflex, coronary artery | LD | Left anterior descending, coronary artery | LM | Left main coronary artery | RC | Right coronary artery | RI | Ramus intermedius | LT | Left side | RT | Right side | 50 | Bilateral |
We are committed to a future of shared success. If you have questions about this communication or need assistance with any other item, contact your provider relationship management representative. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-059530-24-CPN58952 For all claim dispute requests received, 7% are because we don’t receive the proper documentation with claims involving other carriers. When working with another carrier, submit documentation from the other carrier when you send the claim to Anthem to help avoid the claim from denying for timely filing. You can submit the documentation and the claim through Availity Essentials using the Claims and Payments application. If we are the secondary payer, we will need to receive an Explanation of Benefits (EOB) along with the claim submission to determine our payment amount. To avoid a timely filing denial, the documentation must demonstrate that submission to the other insurer was within Anthem’s timely filing limit and must reflect that it was received within the timely filing limit starting from the date of the remittance advice or explanation of payments. If you submit to the other carrier first and receive a rejection, submit the denial letter from the other insurance carrier along with the claim. To avoid a timely filing denial, the denial letter must be dated and printed on letterhead, and the claim and documentation must be submitted to Anthem within the timely filing limit starting from the date of the denial letter. When a claim is submitted to us as the primary payer, and we are the secondary payer, our claims system will deny the claim because we don’t have the EOB. This can delay your receiving payment and can also cause you to miss the timely filing guideline. If you need to dispute a claim due to timely filing, review Timely filing: Acceptable forms of proof. Through our efforts, we are committed to reducing administrative burden and ensuring timely payments because we value you, our care provider partners. ResourceCoordination of benefits — how to avoid timely filing denialsAnthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CM-061099-24 ATTACHMENTS (available on web): Coordination of benefits — how to avoid timely filing denial (pdf - 0.07mb) The Skilled Nursing Facility (SNF) Workforce & Quality Incentive Program (WQIP) incentivizes facilities to improve quality of care, advance equity in healthcare outcomes, and invest in workforce. WQIP functions as a directed payment program in Medi-Cal delivery system for eligible network providers. WQIP is authorized by Welfare & Institutions Code Section 14126.024 (added by Assembly Bill (AB)186 (Chapter 46, Statutes of 2022)) for dates of service January 1, 2023, through December 31, 2026. WQIP succeeds the former SNF Quality and Accountability Supplemental Payment (QASP) program. If you have WQIP program-related questions or concerns, please reach out to WQIP support staff at SNFWQIP@dhcs.ca.gov. DHCS will issue guidance to Anthem later in 2024 to make final payments for CY 2023 based on SNF WQIP-Eligible Days reported to DHCS's data warehouse by June 30, 2024, and final scores for all SNF WQIP metrics including acuity-adjusted staffing hour metrics, staff turnover metric, MDS clinical metrics, claims based clinical metrics, Medi-Cal disproportionate share metric, and MDS racial and ethnic data completeness metric. At this link WQIP Qualifying List is a document with NPIs that DHCS has on file for facilities as of May 7, 2024. If your current or previous NPI is not listed on the WQIP Qualifying List, please email the DHCS SNFWQIP inbox at SNFWQIP@dhcs.ca.gov and complete the form provided in the automatic reply. Note that if an incorrect NPI is listed along with all correct NPIs, there is no reason to reach out to DHCS via email. Please note, only submit one form per facility. The performance period ranges covered in the Quarterly Performance Report #1 below: - Acuity Adjusted Staffing Metrics: April 2023-June 2023
- Staffing Turnover: October 2023 refresh rates:
- With lookback and look-forward quarters: January 2022 to June 2023
- Without lookback and look-forward quarters: April 2022 to March 2023
- MDS Metrics: July 2022 to June 2023
- Medi-Cal Disproportionate Share: January 2023 to June 2023
- Race/Ethnicity Data Completeness: January 2023 to September 2023
If you have any questions, please reach out to AnthemLiaison@anthem.com. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-060213-24 To ensure compliance with the coding and billing of a claim submitted with the diagnosis of sepsis for our pediatric members, we review clinical information (including treatment and medical management) and laboratory and diagnostic procedure findings in the medical records submitted for review. To conduct the review accurately and consistently, our review process for pediatric sepsis applies coding and documentation guidelines. Beginning with admission dates of July 1, 2024, and later for members aged 29 days through 17 years of age, we will also apply the updated and most recent publication of the Society of Critical Care Medicine Pediatric Sepsis Definition Task Force criteria known as the Phoenix Sepsis Criteria, published in the Journal of the American Medical Association (JAMA) in January 2024. Clinicians and facilities should apply the Phoenix Sepsis Criteria when determining at discharge if the pediatric patient’s clinical course supports the coding and billing of a diagnosis of sepsis. The claim may be subject to an adjustment in reimbursement when sepsis is found to be unsupported based on the Phoenix Sepsis Criteria. Together, we can work towards improved outcomes. jamanetwork.com/journals/jama/article-abstract/2814297 Anthem Blue Cross is the trade name of Blue Cross of California. Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, Anthem BC Health Insurance Company, and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. CABC-CDCRCM-056016-24-CPN55116 Maintaining your online provider directory information is essential for member and healthcare partners to connect with you when needed. Access your online provider directory information by visiting anthem.com/ca/provider. Then at the top of the webpage, choose Find Care. Review your information and let us know if any of your information has changed. Updating your informationAnthem uses the provider data management (PDM) capability available on Availity Essentials to update your care provider or facility data. Using the Availity PDM capability meets the quarterly attestation requirement to validate care provider demographic data set by the Consolidated Appropriations Act (CAA). PDM features include:- Updating care provider demographic information for all assigned payers in one location.
- Attesting to and managing current care provider demographic information.
- Monitoring submitted demographic updates in real-time with a digital dashboard.
- Reviewing the history of previously verified data.
Accessing the PDM applicationLog on to Availity.com and select My Providers > Provider Data Management to begin using PDM. Administrators will automatically be granted access to PDM. Additional staff may be given access to PDM by an administrator. To find your administrator, go to My Account Dashboard > My Account > Organization(s) > Administrator Information. PDM training PDM training is available: - Log on to Availity.com to learn about and attend one of our training opportunities.
- On Availity.com, you can view the Availity PDM quick start guide.
- Roster Automation Standard Template and Roster Automation Rules of Engagement training:
- Listen to our recorded webinar on Availity.com.
Not registered for Availity yet?If you aren’t registered to use Availity Essentials, signing up is easy and 100% secure. There is no cost for your care providers to register or to use any of our digital applications. Start by going to Availity.com and selecting New to Availity? Get Started at the top of the home screen to access the registration page. If you have more than one tax ID number (TIN), please ensure you have registered all TINs associated with your account. If you have questions regarding registration, reach out to Availity Client Services at 800-AVAILITY. We are focused on reducing administrative burdens, so you can do what you do best — care for our members. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CM-060902-24-SRS60902 If you and your organization are focused on promoting evidence-based medicine and clinical quality performance, our Alerts Hub clinical notification tool, accessed through Availity Essentials, can help drive your success. Our clinical notification application, Alerts Hub, offers admission, discharge, and transfer (ADT) notifications for Medicare Advantage and Medicaid members. For those members, Alerts Hub offers a simple way to view a list of patients who have been admitted to the hospital or visited the emergency room. Discover what users across the country already know.Alerts Hub offers timely, actionable information to help your organization reach out to patients who can benefit from transitions in care planning or other interventions following inpatient or emergency care. Viewing and responding to ADT notifications with outreach to patients can help drive your organizations’ clinical quality and cost of care performance in value-based care arrangements —More importantly, it helps drive better outcomes for your patients. Get started today.We are committed to finding solutions that help our care provider partners offer quality services to our members. To access Alerts Hub, log on to Availity Essentials, select Payer Spaces, then select Alerts Hub. New users will need to register and set preferences. Registered users will receive daily notification emails with a summary of relevant alerts and a reminder to view details in Alerts Hub. Be sure to check your junk or spam folders if you aren’t receiving messages in your inbox. Need more help? The Availity Custom Learning Center offers a range of training materials that can help you get up to speed quickly so that you can take advantage of all Alerts Hub has to offer. Contact us.Chat with Payer is available during normal business hours. Get answers to your questions about eligibility, benefits, authorizations, claims status, and more. To access Availity Essentials, go to Availity.com and select the appropriate payer space tile from the drop-down. Then, select Chat with Payer and complete the pre-chat form to start your chat. For additional support, visit the Contact Us section of our provider website. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, Anthem BC Health Insurance Company, and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. CABC-CDCR-060624-24-CPN59897 For those providers and their corresponding vendors (either billing services or clearinghouses) who submit corrected claims through EDI, we’re enhancing the 277CA to notify you of submission errors discovered during our claims processing. Although you’ll continue to receive physical mail notifications related to claims processing issues, the 277CA notifications can expedite the turnaround time by highlighting submission issues upfront. Now, the 277CA will also communicate the following messages: - Tax ID and NPI are not registered.
- Billed place of treatment doesn’t correspond with the place of service.
- Rendering provider isn’t valid for the service date.
- Billing NPI doesn’t align with the claim’s tax ID.
Despite the addition of this new feature, there will be no reductions in the services we already provide. Our hope is that this change will augment the speed and communication of our service. Through our efforts, we are committed to reducing administrative burden and ensuring timely payments because we value you, our care provider partners. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CM-060849-24-CPN59863 We hope you are finding our monthly observance articles helpful and informative. We will continue to feature these monthly articles to keep you informed about our resources that are here to support you in caring for all of our members. We strive to advance health equity so everyone has a fair opportunity to be at their healthiest. As we reduce barriers to whole health — physical, behavioral, and social — and personalize the healthcare journey, we can more effectively advance health equity. While focusing on understanding member needs, we actively develop educational tools for providers. In recognition of July as Disability Awareness Month, and to commemorate the signing of the Americans with Disabilities Act (ADA) in 1990 that promotes equal rights and accessibility for people with disabilities, we are introducing three eLearning resources and tools on My Diverse Patients. This site offers a comprehensive repository of resources for providers to help support the needs of diverse patients and address disparities. Availability of multiple free continuing medical education (CME) courses with CMEs are offered through the American Academy of Family Physicians (AAFP). For the month of July, our featured eLearning Resources & Tools are: - Health Equity Framework for People with Disabilities:
- This policy brief provides the rationale for the need for an all-of-government approach to achieve health equity in the United States and its territories for the largest unrecognized minority group in this country — the over 61 million people with disabilities — and sets forth a framework to achieve health equity for all people with disabilities. Disability is a natural part of the human condition, which occurs across all ages, genders, races, ethnicities, languages, and social groups.
- Health Equity for People with Disabilities:
- The CDC’s Division of Human Development and Disability (DHDD) works to promote health and reduce health inequities for people with disabilities of all ages so they can participate fully in all aspects of their communities throughout their lives and have the opportunity to achieve all they set out to do.
- Connections Between Health Equity and Disability:
- When it comes to healthcare, significant disparities abound between people with disabilities and able-bodied people. From physical barriers and discrimination to financial hurdles and a lack of available resources, access to healthcare is alarmingly inequitable for people with disabilities around the world.
We're pleased to offer these resources as we work together to deliver high-quality, equitable healthcare. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, Anthem BC Health Insurance Company, and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. MULTI-ALL-CDCRCM-060726-24-CPN60345 When we receive a corrected claim and it doesn’t have the original claim number, or the original claim number is not correctly entered, we are not able to process it because we’re not able to connect it to the original claim.
- For providers and their vendors (clearinghouses or billing services) submitting a corrected claim through EDI, we will send you a 277CA EDI Response Report acknowledging that we’ve received the submission, but are not able to process it:
- In this instance, you can either submit a new corrected claim with the original claim ID number or submit the corrected claim as an original claim if you do not have the original claim ID number.
- It is important that you submit proof of timely filing of the original claim when submitting a corrected claim so we can ensure the claim is processed according to the timely filing guidelines.
- For providers using Claims Status application on Availity.com, you will not be able to access the corrected claim if it was rejected on the 277CA EDI Response Report:
- In this instance, you can either submit a new corrected claim with the original claim ID number or submit the corrected claim as an original claim if you do not have the original claim ID number.
- It is important that you submit proof of timely filing of the original claim when submitting a corrected claim so we can ensure the claim is processed according to the timely filing guidelines.
We’ve also developed a training video that can help further in reducing duplicate claims along with a training guide called Making the Claims Process Work for You that can help you in properly submitting a corrected claim. Access the video and download the guide here. Provider information is required to view, but it will only occur the first time viewing this training.
If you have questions about submitting a corrected claim, reach out to your provider representative or work with your EDI vendor to ensure you are receiving the 277CA Response Report. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CM-049144-23-CPN48099, CABC-CM-061596-24-CPN61590 Effective September 1, 2024, Anthem will implement facility emergency department leveling. Facilities must use appropriate codes and leveling for all services furnished during the emergency department (ED) encounter. The highest intervention/resource used determines the final facility ED level, which the Special Investigations (SIU) Prepayment Review team assesses for care providers under investigation who are also participating in the prepayment review program. Contact usAvaility Chat with Payer is available during normal business hours. Get answers to your questions about eligibility, benefits, authorizations, claims status, and more. To access Availity Essentials, go to Availity.com, select state and the appropriate payer space tile from the drop-down. Then, select Chat with Payer and complete the pre-chat form to start your chat. For additional support, visit the Contact Us section on our care provider website for the appropriate contact. Please note: This policy does not apply for providers using the enhanced ambulatory patient grouping (EAPG) pricing methodology. With your help, we can continually build towards a future of shared success. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-060122-24-CPN59855 SummaryOn November 17, 2023, and March 21, 2024, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other providers in your practice and office staff. Please note: - The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised | July 6, 2024 | *CC-0261 | Winrevair (sotatercept-csrk) | New | July 6, 2024 | *CC-0125 | Opdivo (nivolumab) | Revised | July 6, 2024 | *CC-0003 | Immunoglobulins | Revised | July 6, 2024 | CC-0033 | Xolair (omalizumab) | Revised | July 6, 2024 | *CC-0062 | Tumor Necrosis Factor Antagonists | Revised | July 6, 2024 | CC-0121 | Gazyva (obinutuzumab) | Revised | July 6, 2024 | CC-0201 | Rybrevant (amivantamab-ymjw) | Revised | July 6, 2024 | *CC-0251 | Ycanth (cantharidin) | Revised |
Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CR-059941-24-CPN59599 Effective August 27, 2024 Summary: On May 19, 2023, August 18, 2023, November 17, 2023, December 11, 2023, and February 23, 2024, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. If you have questions or need additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other providers in your practice and office staff. Please note: - The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised | August 27, 2024 | *CC-0258 | iDoseTR (travoprost Implant) | New | August 27, 2024 | *CC-0259 | Amtagvi (lifleucel) | New | August 27, 2024 | *CC-0260 | Nexobrid (anacaulase-bcdb) | New | August 27, 2024 | *CC-0199 | Empaveli (pegcetacoplan) | Revised | August 27, 2024 | *CC-0041 | Complement Inhibitors | Revised | August 27, 2024 | CC-0128 | Tecentriq (atezolizumab) | Revised | August 27, 2024 | CC-0116 | Bendamustine agents | Revised | August 27, 2024 | CC-0161 | Sarclisa (isatuximab-irfc) | Revised | August 27, 2024 | CC-0158 | Enhertu (fam-trastuzumab deruxtecan-nxki) | Revised | August 27, 2024 | CC-0157 | Padcev (enfortumab vedotin) | Revised | August 27, 2024 | CC-0230 | Adstiladrin (nadofaragene firadenovec-vncg) | Revised | August 27, 2024 | *CC-0125 | Opdivo (nivolumab) | Revised | August 27, 2024 | *CC-0119 | Yervoy (ipilimumab) | Revised | August 27, 2024 | *CC-0099 | Abraxane (paclitaxel, protein bound) | Revised | August 27, 2024 | *CC-0093 | Docetaxel (Taxotere) | Revised | August 27, 2024 | *CC-0094 | Pemetrexed (Alimta, Pemfexy, Pemrydi) | Revised | August 27, 2024 | CC-0130 | Imfinzi (durvalumab) | Revised | August 27, 2024 | *CC-0088 | Elzonris (tagraxofusp-erzs) | Revised | August 27, 2024 | *CC-0118 | Radioimmunotherapy and Somatostatin Receptor Targeted Radiotherapy (Azedra, Lutathera, Pluvicto, Zevalin) | Revised | August 27, 2024 | *CC-0112 | Xofigo (Radium Ra 223 Dichloride) | Revised | August 27, 2024 | *CC-0123 | Cyramza (ramucirumab) | Revised | August 27, 2024 | *CC-0131 | Besponsa (inotuzumab ozogamicin) | Revised | August 27, 2024 | CC-0121 | Gazyva (obinutuzumab) | Revised | August 27, 2024 | CC-0122 | Arzerra (ofatumumab) | Revised | August 27, 2024 | CC-0232 | Lunsumio (mosunetuzumab-axgb) | Revised | August 27, 2024 | CC-0109 | Zaltrap (ziv-aflibercept) | Revised | August 27, 2024 | CC-0135 | Melanoma Vaccines | Revised | August 27, 2024 | *CC-0096 | Asparagine Specific Enzymes | Revised | August 27, 2024 | CC-0120 | Kyprolis (carfilzomib) | Revised | August 27, 2024 | *CC-0117 | Empliciti (elotuzumab) | Revised | August 27, 2024 | *CC-0126 | Blincyto (blinatumomab) | Revised | August 27, 2024 | CC-0113 | Sylvant (siltuximab) | Revised | August 27, 2024 | CC-0132 | Mylotarg (gemtuzumab ozogamicin) | Revised | August 27, 2024 | CC-0097 | Vidaza (azacitidine) | Revised | August 27, 2024 | CC-0129 | Bavencio (avelumab) | Revised | August 27, 2024 | *CC-0090 | Ixempra (ixabepilone) | Revised | August 27, 2024 | CC-0110 | Perjeta (pertuzumab) | Revised | August 27, 2024 | *CC-0115 | Kadcyla (ado-trastuzumab) | Revised | August 27, 2024 | *CC-0108 | Halaven (eribulin) | Revised | August 27, 2024 | CC-0089 | Mozobil (plerixafor) | Revised | August 27, 2024 | CC-0124 | Keytruda (pembrolizumab) | Revised | August 27, 2024 | *CC-0002 | Colony Stimulating Factor Agents | Revised | August 27, 2024 | *CC-0212 | Tezspire (tezepelumab-ekko) | Revised | August 27, 2024 | *CC-0033 | Xolair (omalizumab) | Revised | August 27, 2024 | *CC-0043 | Monoclonal Antibodies to Interleukin-5 | Revised | August 27, 2024 | *CC-0029 | Dupixent (dupilumab) | Revised | August 27, 2024 | *CC-0208 | Adbry (tralokinumab) | Revised | August 27, 2024 | *CC-0062 | Tumor Necrosis Factor Antagonists | Revised | August 27, 2024 | *CC-0067 | Prostacyclin Infusion and Inhalation Therapy | Revised | August 27, 2024 | *CC-0066 | Monoclonal Antibodies to Interleukin-6 | Revised | August 27, 2024 | *CC-0064 | Interleukin-1 Inhibitors | Revised | August 27, 2024 | *CC-0057 | Krystexxa (pegloticase) | Revised | August 27, 2024 | *CC-0068 | Growth Hormones | Revised | August 27, 2024 | *CC-0047 | Trogarzo | Revised | August 27, 2024 | *CC-0078 | Orencia (abatacept) | Revised | August 27, 2024 | *CC-0020 | Natalizumab Agents (Tysabri, Tyruko) | Revised | August 27, 2024 | *CC-0174 | Kesimpta (ofatumumab) | Revised | August 27, 2024 | *CC-0011 | Ocrevus (ocrelizumab) | Revised |
Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-058997-24-CPN57972 Summary: On February 24, 2023, September 11, 2023, and November 17, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other providers in your practice and office staff. Please note: - The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective Date | Clinical Criteria Number | Clinical Criteria Title | New or Revised | July 7, 2024 | *CC-0252 | Adzynma (ADAMTS13, recombinant-krhn) | New | July 7, 2024 | *CC-0253 | Aphexda (motixafortide) | New | July 7, 2024 | *CC-0254 | Zilbysq (zilucoplan) | New | July 7, 2024 | CC-0130 | Imfinzi (durvalumab) | Revised | July 7, 2024 | CC-0223 | Imjudo (tremelimumab-actl) | Revised | July 7, 2024 | *CC-0059 | Selected Injectable NK-1 Antiemetic Agents | Revised | July 7, 2024 | CC-0074 | Akynzeo (fosnetupitant and palonosetron) for injection | Revised | July 7, 2024 | *CC-0065 | Agents for Hemophilia A and von Willebrand Disease | Revised | July 7, 2024 | CC-0124 | Keytruda (pembrolizumab) | Revised | July 7, 2024 | CC-0150 | Kymriah (tisagenlecleucel) | Revised | July 7, 2024 | CC-0187 | Breyanzi (lisocabtagene maraleucel) | Revised | July 7, 2024 | CC-0133 | Aliqopa (copanlisib) | Revised | July 7, 2024 | CC-0205 | Fyarro (sirolimus albumin bound) | Revised | July 7, 2024 | CC-0127 | Darzalex (daratumumab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) | Revised | July 7, 2024 | *CC-0226 | Elahere (mirvetuximab) | Revised | July 7, 2024 | CC-0125 | Opdivo (nivolumab) | Revised | July 7, 2024 | CC-0058 | Sandostatin and Sandostatin LAR (Octreotide) / Octreotide Agents | Revised | July 7, 2024 | *CC-0009 | Lemtrada (alemtuzumab) for the Treatment of Multiple Sclerosis | Revised | July 7, 2024 | *CC-0014 | Beta Interferons and Glatiramer Acetate for Treatment of Multiple Sclerosis | Revised | July 7, 2024 | *CC-0011 | Ocrevus (ocrelizumab) | Revised | July 7, 2024 | *CC-0174 | Kesimpta (ofatumumab) | Revised | July 7, 2024 | *CC-0020 | Natalizumab Agents (Tysabri, Tyruko) | Revised | July 7, 2024 | *CC-0032 | Botulinum Toxin | Revised | July 7, 2024 | *CC-0068 | Growth Hormone | Revised | July 7, 2024 | *CC-0173 | Enspryng (satralizumab-mwge) | Revised | July 7, 2024 | *CC-0170 | Uplizna (inebilizumab-cdon) | Revised | July 7, 2024 | *CC-0199 | Empaveli (pegcetacoplan) | Revised | July 7, 2024 | *CC-0041 | Complement Inhibitors | Revised | July 7, 2024 | *CC-0071 | Entyvio (vedolizumab) | Revised | July 7, 2024 | *CC-0064 | Interleukin-1 Inhibitors | Revised | July 7, 2024 | *CC-0042 | Monoclonal Antibodies to Interleukin-17 | Revised | July 7, 2024 | *CC-0066 | Monoclonal Antibodies to Interleukin-6 | Revised | July 7, 2024 | *CC-0050 | Monoclonal Antibodies to Interleukin-23 | Revised | July 7, 2024 | *CC-0078 | Orencia (abatacept) | Revised | July 7, 2024 | *CC-0063 | Ustekinumab Agents | Revised | July 7, 2024 | *CC-0062 | Tumor Necrosis Factor Antagonists | Revised | July 7, 2024 | CC-0003 | Immunoglobulins | Revised | July 7, 2024 | *CC-0002 | Colony Stimulating Factor Agents | Revised | July 7, 2024 | CC-0247 | Beyfortus (nirsevimab) | Revised | July 7, 2024 | CC-0072 | Vascular Endothelial Growth Factor (VEGF) Inhibitors | Revised | July 7, 2024 | CC-0010 | Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors | Revised | July 7, 2024 | CC-0209 | Leqvio (inclisiran) | Revised | July 7, 2024 | *CC-0182 | Iron Agents | Revised | July 7, 2024 | *CC-0086 | Spravato (esketamine) Nasal Spray | Revised |
Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CR-050482-24-CPN49884 This article was updated as of August 23, 2024. Effective September 1, 2024, Anthem will transition to the following Carelon Medical Benefits Management Clinical Appropriateness Guidelines for medical necessity/clinical appropriateness reviews for requested interventions. This article is to communicate the plan adoption of these Carelon Medical Benefits Management, Inc. guidelines. This does not equate to the presence of a prior authorization requirement. In the event a prior authorization requirement for these services will be implemented, a separate notice will be distributed before the addition of any prior authorization requirements. - Site of Care Guidelines:
- Site of Care for Advanced Imaging
- Rehabilitative Site of Care
- Surgical Site of Care
Please share this notice with other members of your practice and office staff. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-055204-24-CPN54524, MULTI-ALL-CDCR-066460-24 Effective for dates of service on and after October 20, 2024, the following updates will apply to the Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines. As part of the Carelon Medical Benefits Management guideline annual review process, these updates are focused on advancing efforts to drive clinically appropriate, safe, and affordable healthcare services. Radiology:- Brain Imaging:
- Added indications for MRI and amyloid beta PET imaging in Alzheimer disease to address patients considering or receiving lecanemab
- Spine Imaging:
- Changed Perioperative and Periprocedural Imaging to Postoperative and Postprocedural Imaging; pre-procedure requests should be reviewed based on more specific indication
- Extremity Imaging:
- Separated criteria for osteomyelitis and septic arthritis into separate indications; US or arthrocentesis as preliminary tests were placed only in the septic arthritis indication
- Vascular Imaging:
- CTA/MRA Head addition for chronic posterior circulation Stroke/TIA presentations (CTA/MRA neck already allowed, intracranial eval needed for full extent of anatomy)
- Lower Extremity PAD: Updated physiologic testing parameters and added allowance for ischemic signs/symptoms at presentation, in alignment with ACR Appropriateness Criteria
- Suboptimal imaging option downgrades/removals in Brain, Head and Neck, and Abdomen/Pelvis
Cardiovascular:- Imaging of the Heart:
- Resting Transthoracic Echocardiography (TTE)
- Expanded frequency of echocardiographic evaluation in patients on mavacamten for treatment of hypertrophic obstructive cardiomyopathy (HOCM)
- Expanded criteria for echocardiographic evaluation to allow a single screening for cardiac disease in patients undergoing evaluation for solid organ or hematopoietic cell transplant
- Cardiac Resynchronization Therapy:
- Added exclusion for Wireless CRT
- Diagnostic Coronary Angiography:
- Criteria reaffirmed — no changes
- Endovascular Revascularization:
- Added indication for endovascular venous arterialization of the tibial or peroneal veins
- Added exclusions for endovenous femoral-popliteal arterial revascularization with transcatheter placement of intravascular stent and intravascular lithotripsy
- Also added exclusion for atherectomy (clarification)
- Implantable Cardioverter Defibrillators:
- Transvenous ICD placement
- Expanded criteria for transvenous ICD to include phospholamban, filamin-C, and lamin A/C cardiomyopathies
- Percutaneous Coronary Intervention:
- Added exclusion for percutaneous transluminal coronary lithotripsy
- Permanent Implantable Pacemakers:
- Device replacement
- Added criteria for permanent implantable pacemaker device replacement
- Single chamber leadless pacemakers
- Clarified that criteria for single chamber leadless pacemaker apply to the right ventricle
- Added exclusion for right atrial single chamber leadless pacemakers
- Dual chamber leadless pacemakers
- Added exclusion for dual chamber leadless pacemakers
Genetic Testing:- Chromosomal Microarray Analysis:
- Clarified recommendations for Genetic Counseling
- Clarified requirements for postnatal evaluation of individuals with:
- Congenital or early onset epilepsy (before age 3 years) without suspected environmental causes
- Autism spectrum disorder, developmental delay, or intellectual disability with no identifiable cause (idiopathic)
- Clarified prenatal evaluation of a fetus with a structural fetal anomaly noted on ultrasound
- Pharmacogenomic Testing:
- Polygenic Risk Scores renamed Predictive and Prognostic Polygenic Testing:
- Broadened guideline scope to include polygenic expression prognostic testing and multivariable prognostic genetic testing (essentially clarifications), and moved these tests to exclusions as they are considered not medically necessary
- Retitled guideline to Predictive and Prognostic Polygenic Testing to address this change in scope.
- Somatic Testing of Solid Tumors:
- Breast Cancer
- Clarified gene expression profiling is to guide adjuvant therapy for localized Breast Cancer
- Whole Exome and Whole Genome Sequencing:
- Expanded WES criteria to include congenital or early onset epilepsy (before age 3) without suspected environmental etiology and added other clarifications.
- Clarified well-delineated genetic syndrome in criterion for multiple anomalies
- Clarified Genetic Counseling details for WES
MSK:- Sacroiliac Joint Fusion:
- New medical necessity criteria for open SI joint fusion
- As an adjunct to sacrectomy or partial sacrectomy related to tumors involving the sacrum
- As an adjunct to the medical treatment of sacroiliac joint infection/sepsis (for example, osteomyelitis, pyogenic sacroiliitis)
- For severe traumatic injuries associated with pelvic ring disruption (for example, pelvic ring fractures, acetabular fracture, spinopelvic dissociation)
- During multi-segment spinal constructs (for example, correction of deformity in scoliosis or kyphosis surgery) extending to the ilium as part of medically necessary lumbar spine fusion procedures
- Open SI joint fusion is not medically necessary for poorly defined low back pain and sacral insufficiency fractures.
- Spine Surgery:
- Lumbar Discectomy, Foraminotomy, and Laminotomy
- Added exclusion for annular closure device
- Lumbar Laminectomy
- Expanded timeframe for imaging lumbar disc herniation (9 months) and lumbar spinal stenosis (12 months)
Radiation Oncology:- Removed criteria for hyperthermia
- Clarified inclusion criteria of the RTOG 1112 protocol.
Sleep Disorder Management:- Expanded definitions and terminology
- Expanded documentation of hypoventilation
- Expanded criteria for home and in-lab sleep studies
- Added contraindication to APAP titration for use of supplemental oxygen
- Removed home sleep apnea testing (HSAT) as an option in medical necessity of MSLT/MWT for suspected narcolepsy
- Management of OSA using Implanted Hypoglossal Nerve Stimulators — Narrowed age range (raised lower limit to 13) for HNS in individuals with Down syndrome and OSA to align with age range suggested by FDA
- Miscellaneous Devices section added: electronic positional therapy and neuromuscular electrical training of the tongue musculature are considered not medically necessary due to lack of high-quality evidence
As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon Medical Benefits Management using the following: - Access Carelon Medical Benefits Management’s ProviderPortalSM directly at providerportal.com:
- Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.
If you have questions related to guidelines, please contact Carelon Medical Benefits Management via email at MedicalBenefitsManagement.guidelines@Carelon.com. Additionally, you may access and download a copy of the current and upcoming guidelines here. Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CR-059459-24-CPN58860 Effective September 1, 2024, Anthem will upgrade to the 28th edition of MCG Care Guidelines for the following modules. Below is high level summary of the updates and is not intended to be all inclusive: - Behavioral Health Care (BHG):
- The goal length of stay (GLOS) has been changed in two guidelines in the 28th edition of Behavioral Health Care.
- Inpatient & Surgical Care (ISC):
- The goal length of stay (GLOS) has been changed in a total of 72 Optimal Recovery Guidelines in the 28th edition of Inpatient & Surgical Care. In medical Optimal Recovery Guidelines, the GLOS has been changed in 37 guidelines and the GLOS has been changed in 35 surgical Optimal Recovery Guidelines, in the 28th edition of Inpatient & Surgical Care.
- General Recovery Care (GRG):
- The benchmark length of stay (BLOS) has been refined in the 28th edition of General Recovery Care.
- Recovery Facility Care (RFC):
- A total of one guideline has been removed from the 28th edition of Recovery Facility Care.
- Chronic Care (CCG):
- A total of 10 guidelines have been moved in the 28th edition of Chronic Care.
If you have any questions, please contact the Provider Services number on the back of the member's ID card. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-056389-24-CPN55821 The Medical Policies, Clinical Utilization Management (UM) Guidelines, and Third-Party Criteria below were developed and/or revised during Q4 2023. Note, several policies and guidelines were revised to provide clarification only and are not included. Some may have expanded rationales, medical necessity indications or criteria and some may involve changes to policy position statements that might result in services that previously were covered being found to be not medically necessary. Please share this notice with other providers in your practice and office staff. To view a guideline, visit https://providers.anthem.com/california-provider/home and select Resources, then select Medical Policies and Clinical UM Guidelines. Notes/Updates:Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive. - MED.00146 - Gene Therapy for Sickle Cell Disease:
- Outlines the Medically Necessary and Investigational & Not Medically Necessary criteria for Gene therapy for sickle cell disease
- RAD.00068 - Myocardial Strain Imaging:
- Myocardial strain imaging in considered Investigational & Not Medically Necessary for all indications
- SURG.00026 - Deep Brain, Cortical, and Cerebellar Stimulation:
- Reformatted Position Statement and added headers
- Reformatted Medically Necessary statements to move target treatment areas into criteria
- Revised Medically Necessary statement for primary dystonia to remove dystonia manifestation types
- Reformatted Medically Necessary statements for DBS for Parkinson’s, primary dystonia, and OCD
- Reformatted Medically Necessary statements for epilepsy
- Revised DBS for epilepsy Medically Necessary statement regarding non-epileptic seizures
- Revised Position Statement to add revision/replacement Medically Necessary and Investigational & Not Medically Necessary statements for DBS, cortical stimulation, and battery
- Revised and reformatted Investigational & Not Medically Necessary statements
- SURG.00097 - Scoliosis Surgery:
- Revision to Position Statement formatting
- Added Medically Necessary and Investigational & Not Medically Necessary criteria for revision, replacement, or removal of vertebral body tethering to Position Statement
- SURG.00142 - Genicular Procedures for Treatment of Knee Pain:
- Previously titled: Genicular Nerve Blocks and Ablation for Chronic Knee Pain
- Revised title
- Added genicular artery embolization to the scope of document
- Revised Position Statement to add genicular artery embolization as Investigational & Not Medically Necessary
- CG-DME-42 - Continuous Glucose Monitoring Devices:
- Previously titled: Continuous Glucose Monitoring Devices and External Insulin Infusion Pumps
- Revised title
- Moved content related to external insulin pumps to new document CG-DME-51 and automated insulin delivery systems to new document CG-DME-50
- Revised existing Medically Necessary and Not Medically Necessary statements
- CG-DME-52 - Continuous Passive Motion Devices in the Home Setting:
- Use of a continuous passive motion (CPM) device in the home setting is considered Not Medically Necessary for all indications
- CG-MED-94 - Vestibular Function Testing:
- Outlines the Medically Necessary and Not Medically Necessary criteria for vestibular function testing
- CG-SURG-09 - Temporomandibular Disorders:
- Revised formatting of Medically Necessary statement
- Revised surgical procedures criteria
- Added MIRO Therapy to Not Medically Necessary statement
- CG-SURG-70 - Gastric Electrical Stimulation:
- Added Medically Necessary and Not Medically Necessary criteria to Clinical Indications for removal, revision, or replacement of a gastric electrical stimulator
Medical PoliciesOn November 9, 2023, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Anthem. These medical policies take effect July 1, 2024. Publish date | Medical Policy number | Medical Policy title | New or revised | 1/3/2024 | LAB.00026 | Systems Pathology and Multimodal Artificial Intelligence Testing for Prostate Cancer Previously titled: Systems Pathology Testing for Prostate Cancer | Revised | 1/3/2024 | LAB.00046 | Testing for Biochemical Markers for Alzheimer’s Disease | Revised | 1/3/2024 | LAB.00050 | Metagenomic Sequencing for Infectious Disease in the Outpatient Setting | Conversion new | 1/3/2024 | MED.00057 | MRI Guided High Intensity Focused Ultrasound Ablation for Non-Oncologic Indications | Revised | 1/18/2024 | *MED.00146 | Gene Therapy for Sickle Cell Disease | New | 1/3/2024 | *RAD.00068 | Myocardial Strain Imaging | New | 1/3/2024 | SURG.00010 | Treatments for Urinary Incontinence | Revised | 12/28/2023 | *SURG.00026 | Deep Brain, Cortical, and Cerebellar Stimulation | Revised | 12/28/2023 | *SURG.00097 | Scoliosis Surgery | Revised | 1/3/2024 | *SURG.00142 | Genicular Procedures for Treatment of Knee Pain Previously titled: Genicular Nerve Blocks and Ablation for Chronic Knee Pain | Revised | 1/3/2024 | TRANS.00027 | Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors | Revised |
Clinical UM GuidelinesOn November 9, 2023, the MPTAC approved the following Clinical UM Guidelines applicable to Anthem. These guidelines were adopted by the medical operations committee for Medicare Advantage members on January 4, 2024. These guidelines take effect July 1, 2024. Publish date | Clinical UM Guideline number | Clinical UM Guideline title | New or revised | 1/3/2024 | *CG-DME-42 | Continuous Glucose Monitoring Devices Previously titled: Continuous Glucose Monitoring Devices and External Insulin Infusion Pumps | Revised | 1/3/2024 | CG-DME-44 | Electric Tumor Treatment Field (TTF) | Revised | 1/3/2024 | CG-DME-50 | Automated Insulin Delivery Systems | Conversion new | 1/3/2024 | CG-DME-51 | External Insulin Pumps | Conversion new | 1/3/2024 | *CG-DME-52 | Continuous Passive Motion Devices in the Home Setting | New | 1/3/2024 | CG-LAB-25 | Outpatient Glycated Hemoglobin and Protein Testing | Revised | 1/3/2024 | CG-MED-92 | Foot Care Services | Revised | 1/3/2024 | *CG-MED-94 | Vestibular Function Testing | New | 1/3/2024 | *CG-SURG-09 | Temporomandibular Disorders | Revised | 12/28/2023 | *CG-SURG-70 | Gastric Electrical Stimulation | Revised | 1/3/2024 | CG-SURG-94 | Keratoprosthesis | Revised | 12/28/2023 | CG-SURG-95 | Sacral Nerve Stimulation and Percutaneous or Implantable Tibial Nerve Stimulation for Urinary and Fecal Incontinence, Urinary Retention | Revised |
Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CR-056157-24-CPN54635 Effective October 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem for Medicaid members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these PA rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Description | L7510 | Prosthetic Device Repair Rep | L7520 | Repair Prosthesis Per 15 Min |
To request PA, you may use one of the following methods: - Web: Once logged in to Availity Essentials at Availity.com.
- Fax: 800-754-4708
- Phone: 888-831-2246 (Medi-Cal Managed Care)
Not all PA requirements are listed here. Detailed PA requirements are available to care providers on providers.anthem.com/ca on the Resources tab or for contracted care providers by accessing Availity.com. Care providers may also call Provider Services at 800-407-4627 (Outside L.A. County) or 888-285-7801 (L.A. County) for assistance with PA requirements. UM AROW A2023M0965 Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-050741-24-CPN50188 Effective October 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem for Medi-Cal Managed Care (Medi-Cal) members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these PA rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Description | C9790 | Histotripsy (for example, nonthermal ablation via acoustic energy delivery) of malignant renal tissue, including image guidance |
To request PA, you may use one of the following methods: - Web: Once logged in to Availity Essentials at Availity.com.
- Fax: 800-754-4708
- Phone: 888-831-2246 (Medi-Cal)
Not all PA requirements are listed here. Detailed PA requirements are available to care providers on providers.anthem.com/ca on the Resources tab or for contracted care providers by accessing Availity.com. Care providers may also call Provider Services at 800-407-4627 (Outside L.A. County) or 888-285-7801 (L.A. County) for assistance with PA requirements. UM AROW A2023M0967 Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-050771-24-CPN50146 Effective October 1, 2024 Effective October 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem for Medi-Cal members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines (including definitions and specific contract provisions/exclusions), take precedence over these PA rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s):Code | Description | 81173 | AR (androgen receptor) (such as, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence | 81247 | G6PD (glucose-6-phosphate dehydrogenase) (such as, hemolytic anemia, jaundice), gene analysis; common variant(s) (such as, A, A-) | 81249 | G6PD (glucose-6-phosphate dehydrogenase) (such as, hemolytic anemia, jaundice), gene analysis; full gene sequence | 81307 | PALB2 (partner and localizer of BRCA2) (such as, breast and pancreatic cancer) gene analysis; full gene sequence | 81336 | SMN1 (survival of motor neuron 1, telomeric) (such as, spinal muscular atrophy) gene analysis; full gene sequence | 81403 | Molecular pathology procedure, Level 4 (such as, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons): EPCAM (epithelial cell adhesion molecule) (such as, Lynch syndrome), duplication/deletion analysis. | 81405 | Molecular pathology procedure, Level 6 (such as, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, (such as targeted cytogenomic array analysis) [when specified as the following]: ARSA (arylsulfatase A) (such as, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (such as, maple syrup urine disease, type 1A), full gene sequence DBT (dihydrolipoamide branched chain transacylase E2) (such as, maple syrup urine disease type 2), duplication/deletion analysis DHCR7 (7-dehydrocholesterol reductase) (such as, Smith-Lemli-Opitz syndrome), full gene sequence GLA (galactosidase, alpha) (such as, Fabry disease), full gene sequence NLGN3 (neuroligin 3) (such as, autism spectrum disorders), full gene sequence; NLGN4X (neuroligin 4, X-linked) (such as, autism spectrum disorders), full gene sequence OTC (ornithine carbamoyltransferase) (such as, ornithine transcarbamylase deficiency), full gene sequence TGFBR1 (transforming growth factor, beta receptor 1) (such as, Marfan syndrome), full gene sequence TGFBR2 (transforming growth factor, beta receptor 2) (such as, Marfan syndrome), full gene sequence | 81440 | Nuclear encoded mitochondrial genes (such as, neurologic or myopathic phenotypes), genomic sequence panel, must include analysis of at least 100 genes, including BCS1L, C10orf2, COQ2, COX10, DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2, SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, and TYMP |
To request PA, you may use one of the following methods: - Web: Once logged in to Availity Essentials at Availity.com.
- Fax: 800-754-4708
- Phone:
- Medi-Cal: 888-831-2246
- MRMIP: 877-273-4193
Not all PA requirements are listed here. Detailed PA requirements are available to providers on providers.anthem.com/ca on the Resources tab or for contracted providers by accessing Availity.com. For assistance with PA requirements, Providers may also call Provider Services at 800-407-4627 outside of Los Angeles County, and 888-258-7801 within Los Angeles County. UM AROW A202M1371 Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-058679-24-CPN57596 Effective for dates of service on and after October 1, 2024, the specialty Medicare Part B drugs listed in the table below will be included in our precertification review process. Federal and state law, as well as state contract language and CMS guidelines (including definitions and specific contract provisions/exclusions), take precedence over these precertification rules. They must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims. HCPCS codes | Medicare Part B drugs | J3490, J3590 | Amtagvi (lifleucel) | J3490, J3590 | iDoseTR (travoprost implant) |
Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BC-CR-058745-24-CPN58434 The Centers for Medicare & Medicaid Services (CMS) Health Outcomes Survey (HOS) gathers patient-reported health outcomes from members enrolled in Medicare Advantage plans to support quality improvement activities and improve the overall health of members. Increased awareness of all HOS measures can help guide your provider interactions with your patients and positively impact HOS results and can help impact your Star rating. Refer to attachment to view full details Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CR-055924-24-CPN55629 ATTACHMENTS (available on web): Understanding your role in the Health Outcomes Survey (pdf - 0.87mb) |